Global Trade & Foreign Policy Insights
Topics
Contributors
Sort by:
1 result
December 23, 2019
|2 min read
According to news articles published in early December, Veritas Genetics, a Massachusetts-based company that hoped to lower the cost of whole-genome sequencing, is suspending its U.S. operations because of a lack of investment. Articles theorize that the decreased funding was driven mainly by new CFIUS regulations and heightened CFIUS scrutiny.